5 years ago

Microvascular and lymphovascular tumor invasion are associated with poor prognosis and metastatic spread in renal cell carcinoma: A validation study in clinical practice

Arnulf Stenzl, Silvia Ribback, Steffen Rausch, Johannes Heide, Maik Pechoel, Marcus Scharpf, Michela Martino, Andrea Haitel, Tobias Klatte, Martin Burchardt, Shahrokh F. Shariat, Hussam Alkhayyat, Jens Bedke, Uwe Zimmermann, Nils Kroeger, Frank Dombrowski
Objective To validate microvascular (MVI) and lymphovascular (LVI) invasion as a prognostic factor in renal cell carcinoma patients (pts.) Materials and Methods Data of patients with RCC who underwent radical or nephron sparing surgery were prospectively collected from three academic centers. The occurrence of MVI and LVI was determined with standard staining protocols by experienced pathologists at the time of diagnosis. The association of MVI and LVI with clinicopathological data, metastatic spread and cancer-specific survival (CSS) was evaluated with Fisher's exact tests, binary logistic regression analyses and univariable and multivariable Cox proportional hazard regression models. Results MVI was present in 201 of 747 (26.9%) pts. and was associated with advanced TNM stages, high Fuhrman grades and sarcomatoid features (each p<0.001). MVI was associated with a higher rate of metastatic spread. LVI was present in 32 of 573 (5.5%) of pts. and was associated with advanced TNM stages, Fuhrman grade, and sarcomatoid features (each: p<0.001). Two-third of LVI+ pts. died (p<0.001). Both LVI and MVI were significantly associated with CSS in all patients, clear cell RCC, and localized RCC in univariable analysis (each p<0.001). On multivariable analysis, presence of MVI was identified as an independent prognostic factor (hazard ratio (HR) 2.09, p=0.001). Moreover, MVI (odds ratio (OR)=2.7; p=0.001) and not macrovascular invasion (V2) (p=0.895) was an independent predictor of metastatic spread. LVI was the strongest factor associated with metastatic spread (odds ratio (OR) 4.73; 95% CI: 1.84 – 12.14; p=0.001) in all patients and the subgroup of ccRCC pts. (p=0.001). Conclusions The current study validated LVI and MVI as poor prognostic factors in RCC. These findings recommend an evaluation of both variables in the clinical routine setting to facilitate survival prognostication in follow-up protocols and an assignment to adjuvant treatment trials. This article is protected by copyright. All rights reserved.

Publisher URL: http://onlinelibrary.wiley.com/resolve/doi

DOI: 10.1111/bju.13984

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.